Proteogenomic Markers of Chemotherapy Resistance and Response in Triple Negative Breast Cancer

Researchers have identified biological markers in patients with triple-negative breast cancer that are associated with resistance to chemotherapy. The research team used an innovative analytic approach called “microscaled proteogenomics” that they previously developed to analyze tumor biopsies taken from patients with triple-negative breast cancer prior to treatment with carboplatin and docetaxel. Data from standard DNA- and RNA-sequencing approaches were integrated with mass spectrometry–based proteomics and phosphoproteomic analyses to derive more complete molecular portraits of treatment-responsive vs treatment-resistant tumors.